Navigation Links
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome

SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr 25, 2007 - XenoPort, Inc. (Nasdaq: XNPT) today announced top-line results from a Phase 3 clinical trial of XP13512 for the treatment of symptoms of primary restless legs syndrome (RLS). XP13512 demonstrated statistically significant improvements compared to placebo on both of the co-primary endpoints of the trial and was well tolerated.

"These results are very encouraging and represent a major advance for XenoPort, its partners and, potentially, RLS patients," said Ronald W. Barrett, Ph.D., chief executive officer of XenoPort.

This XenoPort study was a 12-week, double-blind, placebo-controlled Phase 3 clinical trial that enrolled 222 patients who were diagnosed with moderate-to-severe primary RLS. Patients were treated with either 1200 mg of XP13512 or placebo, given once per day. The co-primary endpoints for the clinical trial were the change from baseline for the International RLS (IRLS) rating scale score at end of treatment and the percentage of patients showing significant improvement on the Clinical Global Impression of Improvement (CGI-I) scale at end of treatment.

Treatment with 1200 mg of XP13512 was associated with a statistically significant improvement in the co-primary endpoints compared to placebo. Improvements in the IRLS Scale were significantly greater for XP13512 than for placebo (-13.2 vs. -8.8: p=0.0002). At the end of treatment, significantly more patients treated with XP13512 were reported as "much improved" or "very much improved" on the CGI-I scale compared to those treated with placebo (76% vs. 39%: p less than 0.0001).

During treatment over the 12-week period, the most commonly reported adverse events for XP13512 versus placebo were somnolence (26.5% XP13512; 7.4% placebo) and dizziness (19.5% XP13512; 4.6% placebo). There were no reported serious adverse events in XP13512-treated patients.

Dr. Barrett stated, "XP135
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/16/2009)... VIEW, Calif., Dec. 16 ChemoCentryx, Inc. ... in a Phase 2 clinical trial of CCX354, ... specifically target the CCR1 chemokine receptor for the ... is a highly potent and selective antagonist of ... of immune cells, such as monocytes and macrophages, ...
(Date:12/16/2009)... , ... Recruits a Total of Over,640 patients Ahead ... ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical ... innovative treatments for eye,disease, vascular disease and ... enrolment of the second Phase III trial ...
(Date:12/15/2009)... Volcano Corporation (Nasdaq: VOLC ), ... tools - including Fractional Flow Reserve (FFR), Intravascular ... Tomography (OCT) - designed to enhance the diagnosis ... announced today the placement of over 2,500 s5 ... consoles was first launched in April 2006, with ...
Breaking Medicine Technology:ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Volcano Announces Installed Base Growth Milestone 2Volcano Announces Installed Base Growth Milestone 3Volcano Announces Installed Base Growth Milestone 4Volcano Announces Installed Base Growth Milestone 5Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 1Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 2Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 3Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 4Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 5Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 6BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 1BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 2BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 3BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 4Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research 6853 1Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research 6853 2
... participates in a national study to explore new ... Jan. 12 Reproductive Partners Medical Group ... for their excellent IVF success rates and national ... a national, multi-center study exploring new progesterone delivery ...
... (Nasdaq: IDIX ), a biopharmaceutical company engaged ... treatment of human viral and other infectious diseases, today ... IDX184, a liver-targeted nucleotide prodrug candidate for the treatment ... with the U.S. Food and Drug Administration (FDA). The ...
Other Medicine Technology:Reproductive Partners Participates in New IVF Progesterone Delivery System Study 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 3Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 4
(Date:12/16/2009)... Sermo ( http://www.sermo.com ), the world,s ... results of a new Sermo Vitals Report titled ... The report examines physician dialog about diabetes over ... of a variety of topics, including the therapies ... and candid/verbatim comments on issues related to diabetes. ...
(Date:12/16/2009)... WILMINGTON, Delaware, December 16 While ... outsource their accurate forecast models,for new and ... provides,integrated patient-based forecast solutions to various players. ... I, phase II, as well as phase,III. ... launch, product life cycle,management, market entry strategy, ...
(Date:12/16/2009)... Study finds 6- to 11-month interval lessens complication risks , , ... bundle of joy has had such a profound impact on ... take a breath. A new study suggests that you ... pregnant again, and that more than 11 months could be ... interval between pregnancies was less than six months, the chances ...
(Date:12/16/2009)... visitors can earn a free 21-count one week trial bottle sample ... ... MI (PRWEB) December 16, 2009 -- ImmuneResponse247.com announces ... Sample” of Immune Response 247™ 6 Mushroom Formula , with ... Immune Response 247™ 6 Mushroom Formula is packaged in FDA approved ...
(Date:12/16/2009)... The cost of hearing aids has been brought into reach for ... new subscription based hearing plan. , ... (PRWEB) December ... into reach for many Houstonians with the announcement by Hearing Haven, ... benefit by hearing better on the job, and want to improve ...
Breaking Medicine News(10 mins):Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 2Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 3Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Monthly Subscription Hearing Aid Plan Announced for Houston 2
... Lee Baca has justified placing Paris Hilton under house arrest ... seems that Judge Michael T Sauer who ordered her ... was conning doctors. ,On Larry Kings show, Larry Waldie, ... that Sauer didn't care, and that he even hinted that ...
... Many a families summer vacations mean piling into the car ... marred by frequent nausea and vomiting . This means some ... ,Carsickness, a variant of motion sickness, happens when the ... fast and in what direction the body is moving, says ...
... a clinical stage biopharmaceutical company developing targeted monoclonal ... C virus infection, today announced initiation of ... safety and efficacy of its tumor necrosis therapy ... (GBM), a deadly form of brain cancer. ...
... I trials studying REP8839, a novel topical antibiotic that ... skin pathogens including methicillin-resistant S. aureus (MRSA). ... topically applied REP8839 appears safe, well-tolerated and associated with ... which is desirable for a topical antibiotic treatment. Based ...
... Accera, Inc. announced today that recent data from its Phase ... AD may effectively be thought of and treated as diabetes ... to be caused by the accumulation of amyloid beta plaques ... shown that inducing insulin resistance in the brains of mice ...
... drug, Gatifloxacin, is a better treatment for drug- resistant ... a team of researchers led by Dr Buddha Basnyat ... ,As part of the study, researchers compared the effect ... recommended by the World Health Organisation for treating enteric ...
Other Medicine News:Health News:Car Sickness for the Little Ones can Be Prevented 2Health News:Car Sickness for the Little Ones can Be Prevented 3Health News:Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial 2Health News:Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839 2Health News:Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain 2
... aqueous samples of moderate viscosity and density. Proven ergonomic design reduces hand ... Volume Range (ul) ... 1.0~2.0 Imprecision(%) ... 1 ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
Medicine Products: